Lung cancer immunotherapy: progress, pitfalls, and promises

Molecular Cancer

Review

Aritraa Lahiri¹  Purvish Parikh²  Pravin D. Potdar³  Navneet Singh⁴  Manash K. Paul⁵  Avik Maji⁶  Bharti Bisht⁷  Anubhab Mukherjee⁸ 

[1] Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, 741246, Mohanpur, Nadia, West Bengal, India;Department of Clinical Hematology, Mahatma Gandhi Medical College and Hospital, 302022, Jaipur, Rajasthan, India;Department of Medical Oncology, Tata Memorial Hospital, 400012, Mumbai, Maharashtra, India;Department of Molecular Medicine and Stem Cell Biology, Jaslok Hospital and Research Centre, 400026, Mumbai, India;Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, 160012, Chandigarh, India;Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 90095, Los Angeles, CA, USA;Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, 576104, Manipal, Karnataka, India;Department of Radiation Oncology, N. R. S. Medical College & Hospital, 138 A.J.C. Bose Road, 700014, Kolkata, India;Division of Thoracic Surgery, David Geffen School of Medicine, University of California Los Angeles, 90095, Los Angeles, CA, USA;Esperer Onco Nutrition Pvt Ltd, 4BA, 4Th Floor, B Wing, Gundecha Onclave, Khairani Road, Sakinaka, Andheri East, 400072, Mumbai, Maharashtra, India;

关键词: Lung Cancer;    SCLC;    NSCLC;    Immunotherapy;    Nanomedicine;    Cancer Vaccine;    Antibody;    Adaptive cell therapy;    CAR T therapy;    TCR T therapy;    TIL therapy;    Immunomodulators;   

DOI  :  10.1186/s12943-023-01740-y

 received in 2022-05-26, accepted in 2022-08-22,  发布年份 2022

来源: Springer

【 摘 要 】

Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground in the treatment of lung cancer. Recent advances in adoptive cell therapy (CAR T, TCR, TIL), the associated clinical trials on lung cancer, and associated hurdles are discussed in this review. Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies. Accumulating evidence indicates that a loss of effective anti-tumor immunity is associated with lung tumor evolution. Therapeutic cancer vaccines combined with immune checkpoint inhibitors (ICI) can achieve better therapeutic effects. To this end, the present article encompasses a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, the review also explores the implication of nanomedicine in lung cancer immunotherapy as well as the combinatorial application of traditional therapy along with immunotherapy regimens. Finally, ongoing clinical trials, significant obstacles, and the future outlook of this treatment strategy are also highlighted to boost further research in the field.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 3

Fig. 1

Fig. 1

Fig. 1

Fig. 1